BBOT Reports 75% ORR for BBO-8520 + Pembrolizumab in G12C Inhibitor-Experienced NSCLC
BBOT sits 25% above its 52-week low of $7.
Summary
BBOT announced new clinical data for its KRAS G12C inhibitor BBO-8520, including a 75% ORR in combination with pembrolizumab in G12C inhibitor-experienced NSCLC, and a strategic focus on 2L+ NSCLC and KRAS-mutant CRC/PDAC combinations.
Key Events · Product Development and Regulatory · BBOT
-
BBO-8520 + Pembrolizumab Shows 75% ORR
In 2L+ KRAS G12C inhibitor-experienced NSCLC, BBO-8520 plus pembrolizumab achieved 75% ORR at 500 mg QD and 53% ORR across all dose levels (N=17).
-
Monotherapy Data Remains Competitive
BBO-8520 monotherapy in 2L+ G12C inhibitor-naïve NSCLC showed 63% ORR (26/41), 100% disease control rate (41/41), and no grade 3 liver enzyme elevations.
-
Strategic Deprioritization Announced
BBOT deprioritized BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer, focusing capital on 2L+ G12C inhibitor-experienced NSCLC and KRAS-mutant CRC/PDAC combinations.
-
Cash Runway Into 2028
$344.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026, projected to fund operations into 2028.
Analysis · BBOT · Life Sciences
BridgeBio Oncology disclosed new Phase 1 data showing BBO-8520 plus pembrolizumab achieved a 75% objective response rate at the 500 mg dose in KRAS G12C inhibitor-experienced NSCLC patients — a population with no approved targeted therapy. The company also reported 63% ORR for BBO-8520 monotherapy in inhibitor-naïve patients and announced a strategic pivot away from first-line NSCLC and breast cancer toward the 2L+ experienced setting and KRAS-mutant CRC/PDAC combinations. With $344.1M in cash providing runway into 2028, the data supports a differentiated position in a growing market, though the deprioritization of two programs signals capital discipline and portfolio focus.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBOT was trading at $8.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $710.3M. The 52-week trading range was $7.00 to $14.87. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.